We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMadison Waddell
Modified over 2 years ago
© Guidant 2004 Medical Device versus Drug Similarities and Differences Jeng Mah, David Breiter Guidant Corporation FDA Industry Workshop September 16, 2005
© Guidant 2004 Workshop Device vs. Drug - physical DeviceDrug
© Guidant 2004 Workshop Device vs. Drug - functional Device Actions Mechanical Physical Dynamic Adaptive User dependent Device Effects Local Direct/immediate Measurable Reversible Drug Actions Chemical Physiological Fixed Not adaptive Simple Drug Effects Systemic Indirect/deferred Difficult to measure irreversible
© Guidant 2004 Workshop Device vs. Drug - statistical Device Studies May perform multiple adaptive functions (bundled features) Extensive & informative bench and acute tests Non-blinded, non- placebo pivotal studies Automation & decision making Subject specific optimal programming User interface/skill affects/determines out- comes Real time data collection generates lots of data Drug Studies One drug one desired effect (usually), or deal with drug interactions Phase I, II studies serve different purposes Active control, blinded pivotal studies Subjects receive identi- cal, fixed treatments Data collection focuses on final, pragmatic outcomes
© Guidant 2004 Workshop Device vs. Drug - statistical Device Studies Difficult to administer FDA requirement: single pivotal trial Reliability and quality control issues Drug Studies Easy to administer FDA requirement: two pivotal trials Reliability and quality control issues are less prominent
© Guidant 2004 Workshop To test an intelligent device with a new feature: the new feature include one programmable parameter; physician needs to find the optimal setting of each patient based on the responses of an acute test. This parameter can be modified anytime. Questions: how do we model a true device effect adjusted for the physician, parameter, and patient? What is the treatment we are interested in? Feature? Parameter? Programmability? Utility? What is the experimental unit? When do we need to do new studies? An Example
FDA/Industry Workshop September, 19, 2003 Johnson & Johnson Pharmaceutical Research and Development L.L.C. 1 Uses and Abuses of (Adaptive) Randomization:
Analysis by design Statistics is involved in the analysis of data generated from an experiment. It is essential to spend time and effort in advance to.
1 Design of Dose Response Clinical Trials Boston Chapter of ASA April 10, 2006 Naitee Ting, Pfizer Global R&D.
Evaluating health informatics projects Reasons for and problems of evaluation Objective model Subjective model.
An Update on FDAs Critical Path Initiative Statistical Contributions Robert T. ONeill Ph.D. Director, Office of Biostatistics Center for Drug Evaluation.
Drugs vs. Devices Jeng Mah & Gosford A Sawyerr Sept 16, 2005.
FDA/Industry Workshop September 14-16, 2005 Critical Path Initiative: What it means for pharmaceutical industry statisticians Walter Offen, Lilly Brenda.
Randomized controlled trials Hilde Kløvstad Tallin, 6 September 2005.
Gatekeeping Testing Strategies in Clinical Trials Alex Dmitrienko, Ph.D. Eli Lilly and Company FDA/Industry Statistics Workshop September 2004.
1 Chapter 2: Decision Making, Systems, Modeling, and Support Conceptual Foundations of Decision Making The Systems Approach How Support is Provided.
1 Experimentation in Software Engineering: an introduction Mariano Ceccato FBK Fondazione Bruno Kessler
Database Planning, Design, and Administration. Stages of the Database System Development Lifecycle.
Ralf Becker United Nations Statistics Division Adapting statistical classifications to green growth measurement.
Chapter 9 Overview of Alternating Treatments Designs.
Questions What is the relationship between ‘research designs’ and ‘research strategies’? Which method of experiments, within subjects or between subjects.
Patient Selection Markers in Drug Development Programs Michael Ostland Genentech FDA/Industry Statistics Workshop: Washington D.C., September 14 – 16,
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Interim Analysis in Clinical Trials: A Bayesian Approach in the Regulatory Setting Telba Z. Irony, Ph.D. and Gene Pennello, Ph.D. Division of Biostatistics.
Understand and appreciate Object Oriented Programming (OOP) Objects are self-contained modules or subroutines that contain data as well as the functions.
Implementing a participatory ergonomics process. Overview Traditional Ergonomic Practice PE definition/background Who is involved in PE programs PE in.
If you are viewing this slideshow within a browser window, select File/Save as… from the toolbar and save the slideshow to your computer, then open it.
Will G Hopkins Auckland University of Technology Auckland NZ A Spreadsheet for Analysis of Straightforward Controlled Trials exptal control prepost1post2.
Study Design Jason Rock
A Practical Approach to Accelerating the Clinical Development Process Jerald S. Schindler, Dr.P.H. Assistant Vice President Global Biostatistics & Clinical.
Phase II/III Design: Case Study Case study: Seamless Phase II/III Design for Registration Program Jeff Maca, Ph.D. Senior Associate Director Novartis Pharmaceuticals.
Experimental concepts. TheoryTheory. A theory can be defined as a "general principle proposed to explain how a number of separate facts are related." In.
McGraw-Hill/Irwin © 2004 The McGraw-Hill Companies, Inc. All rights reserved
Product strategy Product analysis and description Lecture 7.
Donald T. Simeon Caribbean Health Research Council.
Management Information Systems, 4 th Edition 1 Chapter 12 Decision Support Systems.
© 2016 SlidePlayer.com Inc. All rights reserved.